REDWOOD CITY, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a clinical-stage oncology company developing targeted therapies for patients with RASaddicted cancers, today announced its financial results for the quarter ended June 30, 2024, and provided an update on corporate progress. The company continues making progress on its 2024 development priorities: Advancing its RAS(ON) multi-selective inhibitor RMC-6236 into monotherapy pivotal trials. Pancreatic cancer: The com ...

财务状况 - 公司现金、现金等价物和有价证券总额为15.9亿美元[19] - 现金及可流动性证券余额为15.91亿美元[34] - 营运资金为15.19亿美元[34] - 总资产为18.08亿美元[34] - 总负债为1.90亿美元[34] - 股东权益为16.19亿美元[34] 收入与费用 - 总收入为0美元，较上年同期下降100%[31] - 研发费用为1.35亿美元，较上年同期增加37.6%[31] - 一般及行政费用为2,171万美元，较上年同期增加48.2%[31] - 亏损额为1.33亿美元，较上年同期增加35.5%[31] - 每股亏损0.81美元，较上年同期减少11.9%[31] 业务发展 - 第二季度收入为零，去年同期为3.8百万美元，下降主要是由于2023年终止与赛诺菲的合作协议[20] - 公司计划在2024年第四季度披露RMC-6236单药治疗非小细胞肺癌的更新数据,并启动一项评估RMC-6236治疗既往接受治疗的晚期非小细胞肺癌患者的注册性研究[10] - 公司计划在2024年第四季度披露RMC-9805单药治疗的初步临床药代动力学、安全性、耐受性和抗肿瘤活性数据[14] - 公司计划在2025年上半年披露RMC-6291联合pembrolizumab的初步临床数据[13] 未来展望 - 公司预计2024年全年GAAP净亏损在5.6亿美元至6亿美元之间,其中包括7000万美元至8000万美元的非现金股份支付费用[24] - 公司目前的现金和现金等价物可为计划的运营提供资金支持至2027年[24]

REDWOOD CITY, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the second quarter 2024 on Wednesday, August 7, 2024, after market close. At 4:30 p.m. Eastern Time that day (1:30 p.m. Pacific Time), Revolution Medicines' senior management team will host a webcast to discuss the financial results for the quarter an ...

REDWOOD CITY, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the second quarter 2024 on Wednesday, August 7, 2024, after market close. At 4:30 p.m. Eastern Time that day (1:30 p.m. Pacific Time), Revolution Medicines' senior management team will host a webcast to discuss the financial results for the quarter an ...

文章核心观点 - 公司开发的RAS(ON)多选择性抑制剂RMC-7977单药或与RAS(ON) G12C选择性抑制剂RMC-4998联合,在KRAS突变非小细胞肺癌(NSCLC)的难治性前临床模型中表现出强大的抗肿瘤活性[1][2][3] - 与突变选择性RAS抑制不同,广谱可逆RAS-GTP抑制剂RMC-7977单药可在这些模型中产生持久的抗肿瘤活性,耐药发生率较低,并可能导致少量慢周期持续细胞的出现[2][6] 公司概况 - 公司是一家临床阶段的肿瘤学公司,专注于开发针对RAS依赖型肿瘤的靶向疗法[11] - 公司的研发管线包括RAS(ON)抑制剂和RAS伴侣抑制剂,正处于临床开发阶段[11] 临床开发计划 - 公司正在评估RMC-6236(RAS(ON)多选择性抑制剂)单药治疗G12X、G13X和Q61X突变的晚期实体瘤患者[8] - 公司计划启动RMC-6236单药治疗胰腺癌和NSCLC的关键性研究[8] - RMC-6236正在与pembrolizumab单药或联合化疗评估用于治疗晚期RAS突变实体瘤[8] - RMC-6236正在与RMC-6291(RAS(ON) G12C选择性抑制剂)联合评估用于治疗晚期KRAS G12C突变实体瘤[9]

Original research published in Cancer Discovery reveals a RAS(ON) multi-selective inhibitor exhibited robust anti-tumor activity alone or in combination with a RAS(ON) G12C-selective inhibitor in preclinical models of difficult-to-treat KRAS-mutated non-small cell lung cancer (NSCLC) REDWOOD CITY, Calif., July 11, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the publ ...

The sudden soaring of the stock price can be attributed to the positive investor mindset regarding the progress in the development of Revolution's lead investigational candidate, RMC-6236. The company is currently evaluating RMC-6236 as a monotherapy as well as in combination with other agents in seprate early-stage studies across a variety of oncology indications. Revolution's clinical-stage pipeline also comprises two other early-stage candidates, being devolped for solid tumour indications. Earnings and ...

REDWOOD CITY, Calif., July 08, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will host an investor webcast to provide an update on its RMC-6236 pancreatic ductal adenocarcinoma (PDAC) clinical development program. Speakers will include members of Revolution Medicines' management team, along with Brian M. Wolpin, M.D., M.P.H., professor of medicine at Harvard M ...

The webcast will take place at 8:00 a.m. Eastern Time on Monday, July 15, 2024. To access the live webcast, please visit the "Events & Presentations" page of Revolution Medicines' website at https://ir.revmed.com/events-and-presentations. Additionally, a replay of the webcast will be available on the "Events & Presentations" page of the Revolution Medicines website for at least 14 days following the event. About Revolution Medicines, Inc. REDWOOD CITY, Calif., July 08, 2024 (GLOBE NEWSWIRE) -- Revolution Me ...

NEW YORK, July 8, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Revolution Medicines, Inc. (NASDAQ: RVMD) on behalf of the company's shareholders. The investigation seeks to determine whether Revolution Medicines's directors breached their fiduciary duties in connection with recent corporate actions. If you are a shareholder of Revolution Medicines, Inc. and are interested in obtaining additional information regarding your rights and options, free of charge, please visit us ...